• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

实体瘤嵌合抗原受体 T 细胞治疗的临床研究。

Clinical Investigations of CAR-T Cell Therapy for Solid Tumors.

机构信息

National Health Commission (NHC) Key Laboratory of Pulmonary Immune-Related Diseases, Guizhou Provincial People's Hospital, Guiyang, China.

Clinical Cancer Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Front Immunol. 2022 Jul 18;13:896685. doi: 10.3389/fimmu.2022.896685. eCollection 2022.

DOI:10.3389/fimmu.2022.896685
PMID:35924243
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9339623/
Abstract

Cell therapy is a distinguished targeted immunotherapy with great potential to treat solid tumors in the new era of cancer treatment. Cell therapy products include genetically engineered cell products and non-genetically engineered cell products. Several recent cell therapies, especially chimeric antigen receptor (CAR)-T cell therapies, have been approved as novel treatment strategies for cancer. Many clinical trials on cell therapies, in the form of cell therapy alone or in combination with other treatments, in solid tumors, have been conducted or ongoing. However, there are still challenges since adverse events and the limited efficacy of cell therapies have also been observed. Here, we concisely summarize the clinical milestones of the conducted and ongoing clinical trials of cell therapy, introduce the evolution of CARs, discuss the challenges and limitations of these therapeutic modalities taking CAR-T as the main focus, and analyze the disparities in the regulatory policies in different countries.

摘要

细胞治疗是一种卓越的靶向免疫疗法,具有很大的潜力,可在癌症治疗的新时代治疗实体瘤。细胞治疗产品包括基因工程细胞产品和非基因工程细胞产品。一些最近的细胞疗法,特别是嵌合抗原受体 (CAR)-T 细胞疗法,已被批准为癌症的新型治疗策略。许多细胞疗法的临床试验,无论是单独使用细胞疗法还是与其他治疗方法联合使用,都在实体瘤中进行或正在进行中。然而,仍然存在挑战,因为细胞疗法也观察到了不良反应和有限的疗效。在这里,我们简要总结了已进行和正在进行的细胞治疗临床试验的临床里程碑,介绍了 CAR 的演变,讨论了以 CAR-T 为重点的这些治疗方式的挑战和局限性,并分析了不同国家监管政策的差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d582/9339623/2dc23448140a/fimmu-13-896685-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d582/9339623/6577cc5ca9e1/fimmu-13-896685-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d582/9339623/73a633bac2fd/fimmu-13-896685-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d582/9339623/2dc23448140a/fimmu-13-896685-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d582/9339623/6577cc5ca9e1/fimmu-13-896685-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d582/9339623/73a633bac2fd/fimmu-13-896685-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d582/9339623/2dc23448140a/fimmu-13-896685-g003.jpg

相似文献

1
Clinical Investigations of CAR-T Cell Therapy for Solid Tumors.实体瘤嵌合抗原受体 T 细胞治疗的临床研究。
Front Immunol. 2022 Jul 18;13:896685. doi: 10.3389/fimmu.2022.896685. eCollection 2022.
2
Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.近期关于嵌合抗原受体(CAR)修饰免疫细胞治疗实体瘤和血液恶性肿瘤的研究进展。
Stem Cell Res Ther. 2022 Sep 24;13(1):482. doi: 10.1186/s13287-022-03163-w.
3
Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.嵌合抗原受体 T 细胞疗法:T 细胞内在、T 细胞外在和治疗限制的当前观点。
Cancer J. 2023;29(1):28-33. doi: 10.1097/PPO.0000000000000636.
4
Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.嵌合抗原受体 T 细胞疗法治疗转移性前列腺癌的挑战与展望。
Eur Urol. 2020 Mar;77(3):299-308. doi: 10.1016/j.eururo.2019.08.014. Epub 2019 Aug 28.
5
Current and future concepts for the generation and application of genetically engineered CAR-T and TCR-T cells.当前和未来用于生成和应用基因工程 CAR-T 和 TCR-T 细胞的概念。
Front Immunol. 2023 Mar 6;14:1121030. doi: 10.3389/fimmu.2023.1121030. eCollection 2023.
6
Biomaterials for chimeric antigen receptor T cell engineering.用于嵌合抗原受体 T 细胞工程的生物材料。
Acta Biomater. 2023 Aug;166:1-13. doi: 10.1016/j.actbio.2023.04.043. Epub 2023 May 2.
7
Paving the road to make chimeric antigen receptor-T-cell therapy effective against solid tumors.为嵌合抗原受体-T 细胞疗法有效治疗实体瘤铺平道路。
Cancer Sci. 2022 Dec;113(12):4020-4029. doi: 10.1111/cas.15552. Epub 2022 Sep 13.
8
Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.嵌合抗原受体 T 细胞免疫疗法治疗实体瘤的展望。
Front Immunol. 2018 May 22;9:1104. doi: 10.3389/fimmu.2018.01104. eCollection 2018.
9
Enhancing CAR T-cell therapies against solid tumors: Mechanisms and reversion of resistance.增强 CAR T 细胞疗法治疗实体瘤:机制与耐药逆转。
Front Immunol. 2022 Dec 8;13:1053120. doi: 10.3389/fimmu.2022.1053120. eCollection 2022.
10
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.儿童和青少年癌症嵌合抗原受体T细胞药物开发儿科战略论坛:ACCELERATE与欧洲药品管理局合作,并由美国食品药品监督管理局参与。
Eur J Cancer. 2022 Jan;160:112-133. doi: 10.1016/j.ejca.2021.10.016. Epub 2021 Nov 25.

引用本文的文献

1
Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives.推进基于嵌合抗原受体(CAR)的实体瘤细胞疗法:挑战、治疗策略及展望
Mol Cancer. 2025 Jul 7;24(1):191. doi: 10.1186/s12943-025-02386-8.
2
Nurses' reported training needs for advanced cell therapies: a survey on behalf of the Nurses Group of the EBMT.护士报告的先进细胞疗法培训需求:代表欧洲血液与骨髓移植协会护士小组开展的一项调查
Clin Hematol Int. 2024 Nov 15;6(4):104-113. doi: 10.46989/001c.124593. eCollection 2024.
3
Optogenetically engineered Septin-7 enhances immune cell infiltration of tumor spheroids.

本文引用的文献

1
Cell Therapy: Types, Regulation, and Clinical Benefits.细胞疗法:类型、监管及临床益处
Front Med (Lausanne). 2021 Nov 22;8:756029. doi: 10.3389/fmed.2021.756029. eCollection 2021.
2
Navigating CAR-T cells through the solid-tumour microenvironment.CAR-T 细胞在实体瘤微环境中的行进。
Nat Rev Drug Discov. 2021 Jul;20(7):531-550. doi: 10.1038/s41573-021-00189-2. Epub 2021 May 10.
3
Chemokines and the immune response to cancer.趋化因子与癌症的免疫反应。
光遗传学工程化 Septin-7 增强肿瘤球体中的免疫细胞浸润。
Proc Natl Acad Sci U S A. 2024 Oct 29;121(44):e2405717121. doi: 10.1073/pnas.2405717121. Epub 2024 Oct 23.
4
Immunoproteasome acted as immunotherapy 'coffee companion' in advanced carcinoma therapy.免疫蛋白酶体在晚期癌症治疗中充当免疫疗法的“咖啡伴侣”。
Front Immunol. 2024 Aug 30;15:1464267. doi: 10.3389/fimmu.2024.1464267. eCollection 2024.
5
TALEN-edited allogeneic inducible dual CAR T cells enable effective targeting of solid tumors while mitigating off-tumor toxicity.TALEN 编辑的同种异体诱导性双 CAR T 细胞能够有效靶向实体瘤,同时减轻肿瘤外毒性。
Mol Ther. 2024 Nov 6;32(11):3915-3931. doi: 10.1016/j.ymthe.2024.08.018. Epub 2024 Aug 21.
6
Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors.协同增效的前景:局部干预与 CAR T 细胞疗法在实体肿瘤中的应用。
BioDrugs. 2024 Sep;38(5):611-637. doi: 10.1007/s40259-024-00669-y. Epub 2024 Jul 30.
7
Recruiting In Vitro Transcribed mRNA against Cancer Immunotherapy: A Contemporary Appraisal of the Current Landscape.招募用于癌症免疫治疗的体外转录mRNA:对当前形势的当代评估。
Curr Issues Mol Biol. 2023 Nov 16;45(11):9181-9214. doi: 10.3390/cimb45110576.
8
A dendritic/tumor fusion cell vaccine enhances efficacy of nanobody-based CAR-T cells against solid tumor.树突/肿瘤融合细胞疫苗增强基于纳米抗体的 CAR-T 细胞对实体瘤的疗效。
Theranostics. 2023 Sep 18;13(14):5099-5113. doi: 10.7150/thno.84946. eCollection 2023.
9
Determination of CAR T cell metabolism in an optimized protocol.在优化方案中测定嵌合抗原受体(CAR)T细胞代谢
Front Bioeng Biotechnol. 2023 Jun 20;11:1207576. doi: 10.3389/fbioe.2023.1207576. eCollection 2023.
10
Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy.通过 TALEN 编辑的通用低免疫原性 FAP-CAR T 细胞耗竭基质,使肿瘤抗原靶向 CAR-T 免疫疗法的浸润和抗肿瘤细胞毒性成为可能。
Front Immunol. 2023 May 12;14:1172681. doi: 10.3389/fimmu.2023.1172681. eCollection 2023.
Immunity. 2021 May 11;54(5):859-874. doi: 10.1016/j.immuni.2021.01.012. Epub 2021 Apr 10.
4
Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity.预处理可改变肿瘤微环境,以增强实体瘤嵌合抗原受体T细胞疗法的疗效及内源性保护性免疫。
Mol Ther. 2021 Jul 7;29(7):2335-2349. doi: 10.1016/j.ymthe.2021.02.024. Epub 2021 Feb 27.
5
T cell circuits that sense antigen density with an ultrasensitive threshold.T 细胞具有超敏阈感知抗原密度的回路。
Science. 2021 Mar 12;371(6534):1166-1171. doi: 10.1126/science.abc1855. Epub 2021 Feb 25.
6
Recent advances and discoveries in the mechanisms and functions of CAR T cells.嵌合抗原受体 T 细胞的作用机制及功能的最新进展和发现。
Nat Rev Cancer. 2021 Mar;21(3):145-161. doi: 10.1038/s41568-020-00323-z. Epub 2021 Jan 22.
7
Nanomaterials for T-cell cancer immunotherapy.用于 T 细胞癌症免疫疗法的纳米材料。
Nat Nanotechnol. 2021 Jan;16(1):25-36. doi: 10.1038/s41565-020-00822-y. Epub 2021 Jan 12.
8
The Landscape of Cell and Gene Therapies for Solid Tumors.实体瘤的细胞和基因治疗前景
Cancer Cell. 2021 Jan 11;39(1):7-8. doi: 10.1016/j.ccell.2020.12.005.
9
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide.基于来那度胺调控的可逆转 ON/OFF 开关嵌合抗原受体
Sci Transl Med. 2021 Jan 6;13(575). doi: 10.1126/scitranslmed.abb6295.
10
Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity.通过删除人诱导多能干细胞衍生 NK 细胞中的 CISH 实现代谢重编程促进体内持久性并增强抗肿瘤活性。
Cell Stem Cell. 2020 Aug 6;27(2):224-237.e6. doi: 10.1016/j.stem.2020.05.008. Epub 2020 Jun 11.